Click Here for 5% Off Your First Aladdin Purchase!

IL-6, CAS No.rp174314, Agonist of Interleukin-6 receptor;Agonist of Interleukin-6 receptor; α subunit

  • Moligand™
Features and benefits
    Item Number
    rp174314
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp174314-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp174314-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90

    Basic Description

    Product NameIL-6, CAS No.rp174314
    SynonymsB-cell stimulatory factor 2;CTL differentiation factor;hybridoma growth factor;interferon β2;interleukin-6
    GradeMoligand™
    Action TypeAGONIST
    Mechanism of actionAgonist of Interleukin-6 receptor;Agonist of Interleukin-6 receptor; α subunit

    Associated Targets

    IL6R Tclin Interleukin-6 receptor subunit alpha 0 Activities

    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    IL6ST Tclin Interleukin-6 receptor subunit beta 0 Activities

    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp174314

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate NamesB-cell stimulatory factor 2;CTL differentiation factor;hybridoma growth factor;interferon β2;interleukin-6
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Morjaria JB, Babu KS, Vijayanand P, Chauhan AJ, Davies DE, Holgate ST.  (2011)  Sputum IL-6 concentrations in severe asthma and its relationship with FEV1..  Thorax,  66  (6): (537).  [PMID:20880874]
    2. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S.  (2011)  The pro- and anti-inflammatory properties of the cytokine interleukin-6..  Biochim Biophys Acta,  1813  (5): (878-88).  [PMID:21296109]
    3. Ferreira MA, Matheson MC, Duffy DL, Marks GB, Hui J, Le Souëf P, Danoy P, Baltic S, Nyholt DR, Jenkins M et al..  (2011)  Identification of IL6R and chromosome 11q13.5 as risk loci for asthma..  Lancet,  378  (9795): (1006-14).  [PMID:21907864]
    4. Uddin M, Lau LC, Seumois G, Vijayanand P, Staples KJ, Bagmane D, Cornelius V, Dorinsky P, Davies DE, Djukanović R.  (2013)  EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma..  PLoS ONE,  (9): (e72502).  [PMID:24039773]
    5. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C et al..  (2014)  Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study..  Ann Rheum Dis,  73  (9): (1607-15).  [PMID:24641941]
    6. Engler H, Brendt P, Wischermann J, Wegner A, Röhling R, Schoemberg T, Meyer U, Gold R, Peters J, Benson S et al..  (2017)  Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms..  Mol Psychiatry,  22  (10): (1448-1454).  [PMID:28138158]
    7. Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Wei JC, Shao J et al..  (2016)  Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial..  Mod Rheumatol,  26  (1): (15-23).  [PMID:26358841]
    8. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC et al..  (2017)  The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease..  Brain Behav Immun,  66  (3): (156-164).  [PMID:28676350]
    9. Garbers C, Heink S, Korn T, Rose-John S.  (2018)  Interleukin-6: designing specific therapeutics for a complex cytokine..  Nat Rev Drug Discov,  17  (6): (395-412).  [PMID:29725131]
    10. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S.  (2020)  Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper..  Front Immunol,  11  (3): (1648).  [PMID:32754159]
    11. Hu B, Huang S, Yin L.  (2021)  The cytokine storm and COVID-19..  J Med Virol,  93  (1): (250-256).  [PMID:32592501]
    12. Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y, Fujioka S, Ishida S, Hiwada K.  (1995)  Circulating interleukin-6 levels in patients with bronchial asthma..  Am J Respir Crit Care Med,  151  (5): (1354-8).  [PMID:7735584]
    13. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al..  (2014)  Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling..  MAbs,  (3): (774-82).  [PMID:24670876]

    Solution Calculators